1. |
Tan CS, Lim LW, Ngo WK. Treatment of massive subretinal hemorrhage from polypoidal choroidal vasculopathy and age-related macular degeneration[J]. Int Ophthalmol, 2017, 37(4): 779-780. DOI: 10.1007/s10792-016-0351-z.
|
2. |
Bressler NM, Bressler SB, Childs AL, et al. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report No. 13[J]. Ophthalmology, 2004, 111(11): 1993-2006. DOI: 10.1016/j.ophtha.2004.07.023.
|
3. |
Chang YS, Kim JH, Kim JW, et al. Development of submacular hemorrhage in neovascular age-related macular degeneration: influence on visual prognosis in a clinical setting[J]. Korean J Ophthalmol, 2018, 32(5): 361-368. DOI: 10.3341/kjo.2017.0095.
|
4. |
Cho JH, Ryoo NK, Cho KH, et al. Incidence rate of massive submacular hemorrhage and its risk factors in polypoidal choroidal vasculopathy[J]. Am J Ophthalmol, 2016, 169: 79-88. DOI: 10.1016/j.ajo.2016.06.014.
|
5. |
Inoue N, Kato A, Araki T, et al. Visual prognosis of submacular hemorrhage secondary to age-related macular degeneration: a retrospective multicenter survey[J/OL]. PLoS One, 2022, 17(7): e271447[2022-07-21]. https://pubmed.ncbi.nlm.nih.gov/35862313/. DOI: 10.1371/journal.pone.0271447.
|
6. |
Sniatecki JJ, Ho-Yen G, Clarke B, et al. Treatment of submacular hemorrhage with tissue plasminogen activator and pneumatic displacement in age-related macular degeneration[J]. Eur J Ophthalmol, 2021, 31(2): 643-648. DOI: 10.1177/112067 2119891625.
|
7. |
Ogata M, Oh H, Nakata A, et al. Displacement of submacular hemorrhage secondary to age-related macular degeneration with subretinal injection of air and tissue plasminogen activator[J/OL]. Sci Rep, 2022, 12(1): 22139[2022-12-22]. https://pubmed.ncbi.nlm.nih.gov/36550175/. DOI: 10.1038/s41598-022-26289-6.
|
8. |
Tranos P, Tsiropoulos GN, Koronis S, et al. Comparison of subretinal versus intravitreal injection of recombinant tissue plasminogen activator with gas for submacular hemorrhage secondary to wet age-related macular degeneration: treatment outcomes and brief literature review[J]. Int Ophthalmol, 2021, 41(12): 4037-4046. DOI: 10.1007/s10792-021-01976-x.
|
9. |
Jackson TL, Bunce C, Desai R, et al. Vitrectomy, subretinal tissue plasminogen activator and intravitreal gas for submacular haemorrhage secondary to exudative age-related macular degeneration (TIGER): study protocol for a phase 3, pan-European, two-group, non-commercial, active-control, observer-masked, superiority, randomised controlled surgical trial[J]. Trials, 2022, 23(1): 99. DOI: 10.1186/s13063-021-05966-3.
|
10. |
Fine HF, Iranmanesh R, Del PL, et al. Surgical outcomes after massive subretinal hemorrhage secondary to age-related macular degeneration[J]. Retina, 2010, 30(10): 1588-1594. DOI: 10.1097/IAE.0b013e3181e2263c.
|
11. |
Zhao J, Chandrasekaran PR, Cheong KX, et al. New concepts for the diagnosis of polypoidal choroidal vasculopathy[J/OL]. Diagnostics (Basel), 2023, 13(10): 1680[2023-05-09]. https://pubmed.ncbi.nlm.nih.gov/37238165/. DOI: 10.3390/diagnostics13101680.
|
12. |
Cho SC, Cho J, Park KH, et al. Massive submacular haemorrhage in polypoidal choroidal vasculopathy versus typical neovascular age-related macular degeneration[J/OL]. Acta Ophthalmol, 2021, 99(5): e706-e714[2020-12-02]. https://pubmed.ncbi.nlm.nih.gov/33289345/. DOI: 10.1111/aos.14676.
|
13. |
Anantharaman G, Sheth J, Bhende M, et al. Polypoidal choroidal vasculopathy: Pearls in diagnosis and management[J]. Indian J Ophthalmol, 2018, 66(7): 896-908. DOI: 10.4103/ijo.IJO_1136_17.
|
14. |
Matsuo Y, Haruta M, Ishibashi Y, et al. Visual outcomes and prognostic factors of large submacular hemorrhages secondary to polypoidal choroidal vasculopathy[J]. Clin Ophthalmol, 2021, 15: 3557-3562. DOI: 10.2147/OPTH.S327138.
|
15. |
Confalonieri F, Stene-Johansen I, Lumi X, et al. Intravitreal r-tPA injection and pneumatic displacement for submacular retinal hemorrhage: a case series[J]. Case Rep Ophthalmol Med, 2022, 13(2): 630-637. DOI: 10.1159/000526068.
|
16. |
Moisseiev E, Ami TB, Barak A. Vitrectomy and subretinal injection of tissue plasminogen activator for large submacular hemorrhage secondary to AMD[J]. Eur J Ophthalmol, 2014, 24(6): 925-931. DOI: 10.5301/ejo.5000500.
|
17. |
Boiché M, Angioi-Duprez K, Conart J, et al. Treatment of hematomas in age related macular degeneration by vitrectomy and subretinal injection of r-tPA: preliminary results[J/OL]. J Fr Ophtalmol, 2019, 42(9): e391-e397[2019-08-27]. https://pubmed.ncbi.nlm.nih.gov/31471124/. DOI: 10.1016/j.jfo.2019.07.002.
|
18. |
Fassbender JM, Sherman MP, Barr CC, et al. Tissue plasminogen activator for subfoveal hemorrhage due to age-related macular degeneration: comparison of 3 treatment modalities[J]. Retina, 2016, 36(10): 1860-1865. DOI: 10.1097/IAE.0000000000001030.
|
19. |
Kimura S, Morizane Y, Hosokawa MM, et al. Outcomes of vitrectomy combined with subretinal tissue plasminogen activator injection for submacular hemorrhage associated with polypoidal choroidal vasculopathy[J]. Jpn J Ophthalmol, 2019, 63(5): 382-388. DOI: 10.1007/s10384-019-00679-2.
|
20. |
Bressler SB, Melia M, Glassman AR, et al. Rranibizumb plus prompt or deferred laser for diabetic macular edema in eyes with vitrectomy before anti-vascular endothelial growth factor therapy[J]. Retina, 2015, 35(12): 2516-2528. DOI: 10.1097/IAE.0000000 000000617.
|
21. |
Inoue M, Yamane S, Taoka R, et al. Aflibefcept for polypoidal choroidal vasculopathy: as needed versus fixed interval dosing[J]. Retina, 2016, 36(8): 1527-1534. DOI: 10.1097/IAE.000000 0000000933.
|
22. |
Cho HJ, Kim KM, Kim HS, et al. Intravitreal Aflibercept and Ranibizumab injections for polypoidal choroidal vasculopathy[J]. Am J Ophthalmol, 2016, 165: 1-6. DOI: 10.1016/j.ajo.2016.02.019.
|
23. |
Hikichi T. Six-year outcomes of antivascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy[J]. Br J Ophthalmol, 2018, 102(1): 97-101. DOI: 10.1136/bjophthalmol-2017-310448.
|
24. |
Mayer WJ, Hakim I, Haritoglou C, et al. Efficacy and safety of recombinant tissue plasminogen activator and gas versus Bevacizumab and gas for subretinal haemorrhage[J]. Acta Ophthalmol, 2013, 91(3): 274-278. DOI: 10.1111/j.1755-3768.2011.02264.x.
|
25. |
Kumar A, Roy S, Bansal M, et al. Modified approach in management of submacular hemorrhage secondary to wet age-related macular degeneration[J]. Asia Pac J Ophthalmol (Phila), 2016, 5(2): 143-146. DOI: 10.1097/APO.0000000000000130.
|
26. |
Helaiwa K, Paez LR, Szurman P, et al. Combined administration of preoperative intravitreal and intraoperative subretinal recombinant tissue plasminogen activator in acute hemorrhagic age-related macular degeneration[J/OL]. Cureus, 2020, 12(3): e7229[2020-04-10]. https://pubmed.ncbi.nlm.nih.gov/32190528/. DOI: 10.7759/cureus.7229.
|
27. |
Meyer CH, Scholl HP, Eter N, et al. Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and Bevacizumab: a retrospective pilot study[J]. Acta Ophthalmol, 2008, 86(5): 490-494. DOI: 10.1111/j.1600-0420.2007.01125.x.
|
28. |
Terasaki H, Miyake Y, Kondo M, et al. Focal macular electroretinogram before and after drainage of macular subretinal hemorrhage[J]. Am J Ophthalmol, 1997, 123(2): 207-211. DOI: 10.1016/s0002-9394(14)71037-2.
|
29. |
Ueda-Arakawa N, Tsujikawa A, Yamashiro K, et al. Visual prognosis of eyes with submacular hemorrhage associated with exudative age-related macular degeneration[J]. Jpn J Ophthalmol, 2012, 56(6): 589-598. DOI: 10.1007/s10384-012-0191-y.
|
30. |
Kim KM, Kim JH, Chang YS, et al. Long-term outcomes in patients with neovascular age-related macular degeneration who maintain dry macula after three monthly Ranibizumab injections[J]. Semin Ophthalmol, 2018, 33(3): 371-376. DOI: 10.1080/08820538.2016.1247179.
|
31. |
Coscas F, Coscas G, Lupidi M, et al. Restoration of outer retinal layers after Aflibercept therapy in exudative AMD: prognostic value[J]. Invest Ophthalmol Vis Sci, 2015, 56(6): 4129-4134. DOI: 10.1167/iovs.15-16735.
|
32. |
Kimura S, Morizane Y, Hosokawa M, et al. Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy and subretinal tissue plasminogen activator[J]. Am J Ophthalmol, 2015, 159(4): 683-689. DOI: 10.1016/j.ajo.2014.12.020.
|
33. |
Chang W, Garg SJ, Maturi R, et al. Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration[J]. Am J Ophthalmol, 2014, 157(6): 1250-1257. DOI: 10.1016/j.ajo.2014.02.007.
|
34. |
Patikulsila D, Winaikosol P, Choovuthayakorn J, et al. Pars plana vitrectomy and subretinal tissue plasminogen activator for large exudative submacular hemorrhage: a case series[J]. BMC Ophthalmol, 2022, 22(1): 411. DOI: 10.1186/s12886-022-02639-w.
|